
Barclays lowered the firm’s price target on Collegium Pharmaceutical (COLL) to $41 from $48 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| COLL | Collegium Pharmaceutical | 25.55 | -19.79 | -43.65% |
| Name | Price | % Change | |
|---|---|---|---|
| $25.55 | -43.65% |

Barclays lowered the firm’s price target on Collegium Pharmaceutical (COLL) to $41 from $48 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source

Collegium Pharmaceutical Inc. (($COLL)) has held its Q3 earnings call. Read on for the main highlights of the call. Collegium Pharmaceutical’s earnings call carried a predominantly positive tone, led by

Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on Collegium Pharmaceutical. The associated price target remains the same with $60.00. Brandon Folkes gave his rating based on

Piper Sandler analyst David Amsellem lowered the firm’s price target on Collegium Pharmaceutical (COLL) to $28 from $43 and keeps a Neutral rating on the shares following quarterly results. The

Sees FY26 product revenues $825M-$855M. Sees FY26 JORNAY PM revenue $190M-$200M. Sees FY26 AZSTARYS revenue $65M-$75M. Sees FY26 adjusted EBITDA $445M-$470M. Published first on TheFly – the ultimate source for

Collegium announced a $50M accelerated share repurchase program as part of its broader capital allocation strategy. The final settlement of the accelerated share repurchase is expected to be completed in

Reports Q3 revenue $216.3M, consensus $216.03M. Reports Q3 adjusted EBITDA $121.6M vs. $133.0M last year. “We continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts

Collegium Pharmaceutical ( ($COLL) ) has issued an update. On November 5, 2026, Collegium reported record third-quarter net revenues of $216.3 million, up 3% year over year. JORNAY PM revenue

Collegium Pharmaceutical ( ($COLL) ) has issued an announcement. On October 15, 2026, Collegium Pharmaceutical and Grünenthal GmbH entered into a settlement agreement resolving all disputes, including a U.S. patent

In a regulatory filing, Collegium Pharmaceutical (COLL) noted that the company is party to a license agreement, dated as of January 13, 2015, with Grunenthal GmbH, which the company assumed
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 25, 2027TBA | $793.98M | $1.89 | $222.21M | -3.13 | 20.85 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.